Ardelyx, Inc. (NASDAQ:ARDX) Q1 2026 Earnings Call Transcript
Operator: Welcome to the Ardelyx First Quarter 2026 Earnings Call. All participants will be in a listen-only mode.
Ardelyx Inc. (ARDX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AIGH Investment Partners Orin Hirschman | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.84 | 333,333 | $1,946,331.39 | 3,302,918 | 2026-02-20 | Filing | |
| $3.63 | 200,000 | $725,880.00 | 2,896,871 | 2025-06-16 | Filing | |
| $3.69 | 200,000 | $737,260.00 | 2,696,871 | 2025-06-09 | Filing | |
| $3.29 | 100,000 | $329,120.00 | 2,496,871 | 2025-05-15 | Filing | |
| $4.22 | 381,377 | $1,610,936.45 | 2,396,871 | 2025-05-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.29 | 41,668 | $261,954.22 | 1,795,614 | 2026-04-15 | Filing | |
| $5.84 | 41,666 | $243,329.44 | 1,816,448 | 2026-03-16 | Filing | |
| $6.26 | 41,666 | $260,620.83 | 1,836,153 | 2026-02-24 | Filing | |
| $5.70 | 1 | $5.70 | 339,151 | 2026-02-20 | Filing | |
| $5.71 | 386 | $2,205.53 | 339,152 | 2026-02-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,365,512 | $62,089,417 | 0% | |
| 2. | 6,661,693 | $39,903,541 | 0% | |
| 3. | 5,234,683 | $31,355,751 | 0.01% | |
| 4. | 1,678,111 | $10,051,885 | 0% | |
| 5. | 708,589 | $4,244,448 | 0% |
News See All
Ardelyx, Inc. (NASDAQ:ARDX) Q4 2025 Earnings Call Transcript
Operator: Welcome to the Ardelyx Fourth Quarter 2025 Earnings Conference.
10 Best Long Term Healthcare Stocks to Buy
Investing in healthcare stocks offers a combination of defensive stability and long-term growth potential, supported by consistent demand for medical services, pharmaceuticals, and healthcare technologies...
Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results
TheFly reported on January 29 that TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
10 Best Small-Cap Stocks Ready to Explode in 2026
On January 27, Matt Stucky from Northwestern Mutual appeared on a CNBC Television interview to discuss the performance of small-cap stocks.
10 Fast-Growing Small Cap Stocks to Buy According to Analysts
On October 1, Francis Gannon, Co-Chief Investment Officer and Managing Director at Royce Investment Partners, released a report analyzing small-cap performance during the third quarter of 2025.
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Ardelyx Third Quarter 2025 Earnings Conference Call.
Ardelyx, Inc. (ARDX) Strengthens Global Reach with Kyowa Kirin Deal
Ardelyx, Inc. (NASDAQ:ARDX) stands fourth on our list among the best biotech stocks.
Hedge Fund Resource Center